https://www.selleckchem.com/products/arv-110.html
09, with a 95% confidence interval of 0.51-2.32; P=.83). Median OS was not reached in either group. The overall response rate was 71.4% in the osimertinib monotherapy group and 53.6% in the combination group. The frequency or severity of known adverse events in the combination group was comparable to those with carboplatin and pemetrexed previously reported, and novel adverse events were not observed in this study. This is the first randomised study to investigate the efficacy and safety of the combination of osimertinib and cytotoxic c
Gefällt mir
Kommentar
Teilen
